Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL)
Joint Authority for Päijät-Häme Social and Health Care
The aim of the study is to compare the efficacy of two photosensitizers,
methyl-aminolaevulinate (MAL) and 5-aminolaevulinic nanoemulsion (BF-200 ALA) in the
treatment of facial actinic keratosis. We use randomized, double-blinded prospective study
design. The efficacy will be assessed clinically, histopathologically and
Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)
Biofrontera Bioscience GmbH
The purpose of this study is to evaluate the safety and efficacy of BF-200 ALA (Ameluz)
versus placebo in the field-directed treatment of mild to moderate actinic keratosis with
photodynamic therapy (PDT) when using the BF-RhodoLED lamp.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.